Get the Stockscreener App
6.78
7.50%
-0.55
After Hours:
6.78
Meiragtx Holdings Plc stock is traded at $6.78, with a volume of 1.03M.
It is down -7.50% in the last 24 hours and down -4.91% over the past month.
See More
Previous Close:
$7.33
Open:
$7.08
24h Volume:
1.03M
Relative Volume:
2.32
Market Cap:
$582.74M
Revenue:
$14.02M
Net Income/Loss:
$-84.03M
P/E Ratio:
-4.6122
EPS:
-1.47
Net Cash Flow:
$-125.54M
1W Performance:
-11.83%
1M Performance:
-4.91%
6M Performance:
+62.59%
1Y Performance:
+11.70%
1-Day Range:
$6.63
$7.17
1-Week Range:
$6.63
$7.95
52-Week Range:
$3.85
$8.75
Meiragtx Holdings Plc Stock (MGTX) Company Profile
Name
Meiragtx Holdings Plc
Sector
Industry
Phone
646-860-7985
Address
450 EAST 29TH STREET, NEW YORK, NY
Compare MGTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MGTX
Meiragtx Holdings Plc
|
6.78 | 582.74M | 14.02M | -84.03M | -125.54M | -1.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Meiragtx Holdings Plc Stock (MGTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Resumed | Chardan Capital Markets | Buy |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Sep-15-20 | Resumed | BofA Securities | Buy |
| Sep-03-19 | Initiated | Piper Jaffray | Overweight |
| Feb-27-19 | Reiterated | Chardan Capital Markets | Buy |
| Jul-03-18 | Initiated | Barclays | Overweight |
| Jul-03-18 | Initiated | BofA/Merrill | Buy |
View All
Meiragtx Holdings Plc Stock (MGTX) Latest News
Chardan Capital Forecasts MeiraGTx FY2026 Earnings - MarketBeat
Chardan Capital Comments on MeiraGTx FY2026 Earnings - Defense World
MeiraGTx Holdings plc (NASDAQ:MGTX) Stock Position Increased by Bank of New York Mellon Corp - Defense World
Chardan Capital Forecasts MeiraGTx FY2025 Earnings - Defense World
MeiraGTx Holdings: Gaining Regulatory Focus (NASDAQ:MGTX) - Seeking Alpha
MeiraGTx Holdings plc (NASDAQ:MGTX) Is Expected To Breakeven In The Near Future - Yahoo Finance
Reviewing MeiraGTx (NASDAQ:MGTX) and CRISPR Therapeutics (NASDAQ:CRSP) - Defense World
MeiraGTx (NASDAQ:MGTX) Given New $13.00 Price Target at Royal Bank of Canada - Defense World
MeiraGTx Holdings (MGTX) Partners with Hologen for $200M AI-Powered Parkinson’s Treatment - Insider Monkey
RBC Capital raises MeiraGTx stock price target to $13.00 By Investing.com - Investing.com Canada
RBC Capital raises MeiraGTx stock price target to $13.00 - Investing.com
RBC Raises Price Target on MeiraGTx Holdings to $13 From $11, Keeps Outperform, Speculative Risk - MarketScreener
When the Price of (MGTX) Talks, People Listen - news.stocktradersdaily.com
MeiraGTx (NASDAQ:MGTX) Sees Strong Trading Volume – Here’s Why - Defense World
Top 10 AI News Updates Taking Wall Street By Storm - Insider Monkey
Plaudits For MeiraGTx And Its Parkinson’s AI Pact - insights.citeline.com
US$200M Deal Accelerates Phase 3 Gene Therapy for Parkinsons - Streetwise Reports
MeiraGTx Holdings plc's (NASDAQ:MGTX) 29% Price Boost Is Out Of Tune With Revenues - Simply Wall St
MGTX stock touches 52-week high of $7.9 amid market optimism - Investing.com
MeiraGTx Shares Soar After Joint Venture Deal With Hologen -March 13, 2025 at 03:31 pm EDT - Marketscreener.com
Top Midday Gainers -March 13, 2025 at 02:24 pm EDT - Marketscreener.com
MGTX’s price-to-sales ratio: A comparative analysis with its peers - US Post News
MeiraGTx Holdings plc SEC 10-K Report - TradingView
MeiraGTx earnings beat by $0.08, revenue topped estimates - Investing.com UK
MeiraGTx Collaborates With Hologen AI To Expedite Development Of Parkinson's Candidate, Stock Soars - Benzinga India
MeiraGTx (MGTX) Stock Climbs in Pre-Hour Trading - Stocks Telegraph
MeiraGTx secures $200 million, forms joint venture for CNS drugs By Investing.com - Investing.com Australia
MeiraGTx Secures $200 Mln From Hologen For Phase 3 Dvpt. Of AAV-GAD, Establish Neuro-AI JV - Nasdaq
MeiraGTx Holdings PLC reports results for the quarter ended December 31Earnings Summary - TradingView
MeiraGTx Holdings Announces Joint Venture with Hologen - TipRanks
MeiraGTx secures $200 million, forms joint venture for CNS drugs - Investing.com
MeiraGTx Reports Fourth Quarter and Full Year 2024 Financial and Operational Results and Recent Business Updates - The Manila Times
MeiraGTx stock surges on Hologen AI deal By Investing.com - Investing.com South Africa
MeiraGTx stock surges on Hologen AI deal - Investing.com India
MeiraGTx Enters into a Strategic Collaboration with Hologen AI to Expedite Phase 3 Development of AAV-GAD for Parkinson's Disease and Industrialize MeiraGTx's Proprietary Manufacturing Process - The Manila Times
MeiraGTx and Hologen Limited Announce $200 Million Collaboration and Formation of Hologen Neuro AI Ltd Joint Venture for Parkinson's Disease Development - Nasdaq
Piper Sandler maintains Overweight on MeiraGTx stock, $26 target By Investing.com - Investing.com South Africa
Piper Sandler maintains Overweight on MeiraGTx stock, $26 target - Investing.com India
MeiraGTx Holdings PLC expected to post a loss of 56 cents a shareEarnings Preview - TradingView
MeiraGTx Holdings plc (NASDAQ:MGTX) Shares Purchased by Rhumbline Advisers - Defense World
MeiraGTx (MGTX) Projected to Post Quarterly Earnings on Thursday - Defense World
(MGTX) Investment Analysis - Stock Traders Daily
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
MeiraGTx (NASDAQ:MGTX) Receives "Buy" Rating from Chardan Capital - MarketBeat
MeiraGTx Holdings plc (MGTX) expanding its growth trajectory ahead - SETE News
MeiraGTx’s (MGTX) Buy Rating Reaffirmed at Chardan Capital - Defense World
MeiraGTx seeks UK approval after gene therapy restores sight in children born blind - Yahoo Finance
MeiraGTx (NASDAQ:MGTX) Reaches New 52-Week High – What’s Next? - Defense World
Long Term Trading Analysis for (MGTX) - news.stocktradersdaily.com
MeiraGTx rises after publication of positive data from gene therapy trial for eye disorder - Seeking Alpha
Meiragtx’s gene therapy shows ‘exceptional’ data for blind children - BioWorld Online
Meiragtx Holdings Plc Stock (MGTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):